You can not select more than 25 topics
Topics must start with a letter or number, can include dashes ('-') and can be up to 35 characters long.
91 lines
3.5 KiB
91 lines
3.5 KiB
<navbar custom-style="background:{{background}}" fixed> |
|
<van-icon name="arrow-left" slot="left" size="18px" color="#000" bind:tap="handleBack" /> |
|
</navbar> |
|
<view |
|
class="page" |
|
style="background: url('{{imageUrl}}bg15.png?t={{Timestamp}}') no-repeat top center/100% 518rpx;padding-top:{{pageTop+20}}px;" |
|
> |
|
<view class="module1" style="background: url('{{imageUrl}}bg16.png?t={{Timestamp}}') no-repeat top center/100%"> |
|
<view class="content"> |
|
<view> |
|
研究表明，GO-QOL生活质量评估能敏锐反映患者的主观感受变化，是评估治疗效果的重要工具。 |
|
<text class="reference">[1]</text> |
|
</view> |
|
<view>它不仅能帮你看清自己“主观世界”的变化还能成为你和医生沟通的重要桥梁。</view> |
|
</view> |
|
<view class="container"> |
|
<view class="title">适用场景</view> |
|
<view class="progress"> |
|
<view class="row"> |
|
<view class="aside"> |
|
<view class="line-top" style="opacity: 0"></view> |
|
<view class="side"></view> |
|
<view class="line"></view> |
|
</view> |
|
<view class="r-content"> |
|
<text class="name">初诊时:</text> |
|
作为基线记录生活影响 |
|
<text class="reference">[3]</text> |
|
</view> |
|
</view> |
|
<view class="row"> |
|
<view class="aside"> |
|
<view class="line-top"></view> |
|
<view class="side"></view> |
|
<view class="line"></view> |
|
</view> |
|
<view class="r-content"> |
|
<text class="name">诊疗中:</text> |
|
分数上升说明主观改善 |
|
<text class="reference">[4]</text> |
|
</view> |
|
</view> |
|
<view class="row"> |
|
<view class="aside"> |
|
<view class="line-top"></view> |
|
<view class="side"></view> |
|
<view class="line"></view> |
|
</view> |
|
<view class="r-content"> |
|
<text class="name">病情期:</text> |
|
判断是否还需更多支持 |
|
<text class="reference">[2-3]</text> |
|
</view> |
|
</view> |
|
</view> |
|
</view> |
|
<view class="tip"> |
|
共 |
|
<text class="num">16</text> |
|
题，可能会占用您3分钟 |
|
</view> |
|
</view> |
|
<view class="module2"> |
|
<view class="title">参考文献:</view> |
|
<view class="content"> |
|
<view> |
|
[1]Kahaly, George J et al.“Teprotumumab lmproves Quality of Life in Thyroid Eye Disease: Meta-analysis and |
|
Matching adjusted Indirect Comparison." Journal of the EndocrineSociety vol.9,6 bvaf063.8 Apr.2025 |
|
</view> |
|
<view> |
|
[2] Lee, T.H.B., & Sundar, G.(2020). Quality of Life in ThyroidEye Disease: A Systematic Review.Ophthalmic |
|
plastic andreconstructive surgery,36(2),118-126. |
|
</view> |
|
<view> |
|
[3] Dietrich A, Taylor P, White P, et al. Establishing theusefulness of the GO-QOL in a UK hospital-treated |
|
populationwith thyroid eye disease in the ClRTED trial. Psychol HealthMed.2018;23(sup1):1341-1355. |
|
</view> |
|
<view> |
|
[4] Smith TJ, Cockerham K, Barretto N, et al. Bridging andValidation of the Specific Graves Ophthalmopathy |
|
Quality ofLife Questionnaire With Health State Utility Values. EndocrPract.2024;30(5):470-475. |
|
</view> |
|
</view> |
|
</view> |
|
<view class="footer"> |
|
<button class="share" open-type="share"> |
|
<image class="icon" src="{{imageUrl}}icon69.png?t={{Timestamp}}"></image> |
|
<view class="name">分享</view> |
|
</button> |
|
<view class="btn" bind:tap="handleAdd">开始评测</view> |
|
</view> |
|
</view>
|
|
|